Stocks Health care ZURA
NASDAQ · Health careZura Bio Ltd (ZURA)
It posted a net loss of $93.5M. In fiscal 2025 capital spending exceeded operating cash flow by $64.9M. At September 30, 2026 it held $187.7M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on October 27, 2026.
Key facts about Zura Bio Ltd
- Net worth
- Zura Bio Ltd has a market value (market cap) of $134.6M at the latest share price, and shareholders' equity of $177.7M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Cash flow
- In fiscal 2025 operations used $64.8M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on October 27, 2026 and covers the period to September 30, 2026. Open on SEC EDGAR
- Next earnings report
- Zura Bio Ltd's next report is expected around February 25, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
What Zura Bio Ltd does
Zura Bio Ltd is registered with the SEC under industry code SIC 2836 (Biological Products, (No Diagnostic Substances)). Its shares trade on NASDAQ under the ticker ZURA.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | n/a | -$68.7M | -$1.06 | -$64.9M |
| 2024 | n/a | -$52.4M | -$0.60 | -$28.2M |
| 2023 | n/a | -$60.4M | -$2.09 | n/a |
| 2022 | n/a | -$25.7M | -$141.97 | n/a |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Latest SEC filings
What Zura Bio Ltd has filed recently, newest first. Each links to the original document on SEC EDGAR.
- November 9, 2026Other event 8-K
- October 27, 2026
- October 27, 2026
- October 27, 2026
- September 30, 2026
- August 17, 2026
- August 11, 2026
- August 11, 2026
- July 1, 2026
- June 18, 2026
Insider trades
What the people running Zura Bio Ltd did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider trades were reported in the last 90 days.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| February 26, 2026 | AI Biotechnology LLC10% owner | Bought | 2,000,000 | $12.5M |
Who owns ZURA
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| AI Biotechnology LLC13D, may seek influence with 3 related filers | 18.2% | March 2, 2026 |
| Athanor Capital13D, may seek influence with 1 related filers | 15.7% | January 27, 2026 |
| Suvretta Capital Management, LLC13G, passive with 2 related filers | 9.9% | May 12, 2026 |
| Venrock Healthcare Capital Partners III, L.P.13G, passive with 6 related filers | 9.9% | May 15, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 95 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| Montanova Capital, LLC | 9,443,001 | +376,000 |
| Venrock Adviser, LLC | 6,434,990 | 0 |
| Mpm Bioimpact LLC | 4,472,843 | new |
| Great Point Partners LLC | 4,215,930 | 0 |
| Jpmorgan Chase & Co | 4,354,715 | -104,136 |
| Braidwell LP | 3,980,295 | -8,694 |
| Siren, L.L.C. | 3,734,866 | 0 |
| BlackRock, Inc. | 3,614,695 | +3,157,336 |
| Commodore Capital LP | 3,250,000 | 0 |
| Adage Capital Partners GP, L.L.C. | 2,750,000 | 0 |
| Saturn V Capital Management LP | 2,101,119 | +1,361,159 |
| QVT Financial LP | 1,895,153 | +584,560 |
| ADAR1 Capital Management, LLC | 1,759,295 | +1,128,892 |
| Armistice Capital, LLC | 1,636,000 | +129,000 |
| Geode Capital Management, LLC | 1,584,209 | +1,056,518 |
| Affinity Asset Advisors, LLC | 1,464,303 | -1,100,000 |
| Stempoint Capital LP | 1,368,215 | -138,825 |
| Ikarian Capital, LLC | 1,218,492 | +25,000 |
| EcoR1 Capital, LLC | 1,179,715 | 0 |
| Vestal Point Capital, LP | 1,173,956 | +662,956 |
Insiders
1 insiders reported holding 6,552,725 shares in total, about $9.2M at the last price.
| Holder | Shares |
|---|---|
| AI Biotechnology LLC10% owner | 6,552,725 |
Questions about ZURA
What does Zura Bio Ltd do?
Zura Bio Ltd is a company in the Health care sector, listed on NASDAQ as ZURA. Its shares trade on NASDAQ under the ticker ZURA.
What is Zura Bio Ltd's net worth?
Zura Bio Ltd has a market value (market cap) of $134.6M at the latest share price, and shareholders' equity of $177.7M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Zura Bio Ltd profitable?
No. Over the twelve months to September 30, 2026 it reported a net loss of $93.5M.
When did Zura Bio Ltd last report?
Its most recent periodic report is the quarterly report (10-Q) filed on October 27, 2026. It covers the period to September 30, 2026. Its newest filing of any kind is the other event from November 9, 2026.
When is Zura Bio Ltd's next earnings report?
Zura Bio Ltd's next report is expected around February 25, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare ZURA with
Follow ZURA
Get an email when Zura Bio Ltd files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Zura Bio Ltd tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.